Friday, February 3, 2012

Study Compares 3 Common Prostate Cancer Treatments (HealthDay)

TUESDAY, Jan. 31 (HealthDay News) --

Experts comparing three leading prostate cancer therapies find external beam radiation therapy to be more toxic and expensive than either surgery or a more localized form of radiation therapy known as brachytherapy.

Brachytherapy, the researchers noted, resulted in the fewest number of toxicities involving their genital or urinary organs. Just 3.4 percent of those treated with this therapy experienced these types of problems, such as a narrowing of the urethra or bladder bleeding. Brachytherapy also had the lowest cost per patient per year of about $2,557.

A slightly higher number (6.7 percent) of those treated with prostatectomy experienced problems with their genital or urinary organs. This treatment, the study revealed, had a total cost of about $3,206 per patient-year.

Meanwhile, just over 7 percent of patients who received external beam radiation therapy had these adverse effects. This was also the most expensive therapy, at $6,412 per patient-year. Similarly, 1.7 percent of patients who underwent the treatment had gastrointestinal effects. In contrast, only 0.1 percent of prostatectomy patients and 0.3 percent of brachytherapy patients experienced these issues.

They added their findings are preliminary and more research is needed to investigate why the three prostate cancer therapies produce different results and whether or not certain types of patients are more vulnerable to the long-term effects of a particular treatment.

Experts said decisions about treating the individual patient remain specific to that patient and his disease, however.


Read the full HealthDay News report:
Study Compares 3 Common Prostate Cancer Treatments

Study questions proton therapy for prostate cancer (AP)

AP - A warning to men considering a pricey new treatment for prostate cancer called proton therapy: research suggests it might have more side effects than traditional radiation does.

A warning to men considering a pricey new treatment for prostate cancer called proton therapy: Research suggests it might have more side effects than traditional radiation does.

A study of Medicare records found that men treated with proton beams later had one-third more bowel problems, such as bleeding and blockages, than similar men given conventional radiation.

It costs around $48,000 — at least twice as much as other prostate radiation treatments. Hospitals are rushing to build proton centers, and nine are operating now — sites include Boston, Chicago, Houston, Philadelphia, Jacksonville, Fla., and Loma Linda, Calif., east of Los Angeles. Promoters often claim it is less likely to cause complications.

"There's no clear evidence that proton therapy is better" for prostate cancer, and the new results suggest it may cause more complications, said Dr. Ronald Chen, a radiation specialist at the University of North Carolina, Chapel Hill.


Read the full AP report:

Study questions proton therapy for prostate cancer

Seed therapy for prostate cancer may zap fertility

NEW YORK (Reuters Health) -

Radioactive "seeds" that are sometimes used to treat early prostate cancer may do widespread damage to the DNA in a man's sperm, a small study finds.

Known as brachytherapy, the treatment involves implanting radiation-emitting pellets into the prostate gland to kill off cancer cells.

The damage, researchers say, would seem to be enough to make a man infertile. And they should be aware of that going into treatment.

Men who are having their prostates surgically removed and still want to have children can opt to bank their sperm ahead of treatment.

Similarly, Fleshner said, "if a man is going for brachytherapy, then sperm-banking may be a good idea."

But in weighing treatment options, any man has to discuss the benefits and risks of each with his doctor, according to Fleshner.

In general, any prostate cancer therapy can have lasting side effects, like urinary incontinence and erectile dysfunction.

And because brachytherapy is used for early-stage prostate cancer, some men who are candidates for it may also be able to delay having any treatment at all.

That's because prostate cancer is often slow-growing and may never advance to the point of threatening a man's life. So many men with early-stage tumors can opt for "active surveillance" -- which means monitoring the prostate cancer over time to see if it's progressing.


Read the full Reuters Health report:
Seed therapy for prostate cancer may zap fertility


Wednesday, January 25, 2012

Drug May Slow Early Prostate Cancer: Study

TUESDAY, Jan. 24 (HealthDay News) --

New research suggests that Avodart, a drug used to treat an enlarged prostate gland, may help slow the progression of early stage prostate cancer, reducing the need for aggressive treatment in some men.

Prostate cancer can grow and spread slowly, which is why some men are urged to engage in so-called watchful waiting when the cancer is first diagnosed. Avodart (dutasteride) may help such men feel comfortable with surveillance as opposed to radical treatment, the researchers noted.

The medication does have side effects, however, including reversible breast enlargement and tenderness and some sexual dysfunction.

Some experts have concerns about 5-alpha reductase inhibitors. The U.S. Food and Drug Administration recently issued a warning that men who take these drugs to treat enlarged prostate glands may be at increased risk for high-grade prostate cancer.

Read the full HealthDay report here:
Drug May Slow Early Prostate Cancer

Saturday, January 7, 2012

Don't believe hype about robot prostatectomy: study

NEW YORK (Reuters Health) -

Older men considering robotic surgery for prostate cancer shouldn't trust the rosy ads promoting the expensive technology over low-tech surgery.


That's according to a new survey that found complaints about sexual problems and urinary leakage were equally common after the two procedures.
"I wasn't surprised at all," said Dr. Otis Brawley, chief medical officer of the American Cancer Society, who wasn't involved in the study.
"Unfortunately, robotic prostatectomy -- like many things in prostate cancer -- has gotten a lot more hype than it should."

Read the full Reuters reporter here:
Don't believe hype about robot prostatectomy

PSA screening doesn't prevent cancer deaths: study

NEW YORK (Reuters Health) -

Annual screening for prostate cancer doesn't cut men's chances of dying from the disease, according to the latest results of a large screening trial.

The results support a previous report by the same researchers that found no difference in deaths seven to 10 years after the screening program started.

They are also consistent with recent draft guidelines from the U.S. Preventive Services Task Force recommending that average-risk men not undergo regular PSA screening, according to a researcher who worked on the study.

Read the full Reuters report here

PSA screening doesn't prevent cancer deaths



Friday, December 30, 2011

Milk intake in teens tied to later prostate cancer

NEW YORK (Reuters Health) -

Older Icelandic men who remember chugging a lot of milk in their teens are three times as likely to be diagnosed with advanced prostate cancer as more-moderate milk drinkers, researchers have found.

"We believe that our data are indeed solid and provide important evidence for the role of adolescence as a 'sensitive period' for prostate cancer development," Johanna Torfadottir, a nutrition scientist and a graduate student at the University of Iceland, told Reuters Health by email.

How much milk men drank had no connection to their risk of early-stage tumors, however. And intake in midlife -- the age group most other studies have focused on -- didn't seem to matter either.

"From these data alone we cannot recommend that teenage boys should chance their dietary habits," she said. "We are only looking at the risk of one disease, prostate cancer, and obviously risks of other conditions, e.g. bone health, need to be considered." "It would be premature to say that drinking milk causes prostate cancer," he told Reuters Health. "You can talk about association, but it is hard to prove causality."

Dr. Matthew Cooperberg, a urologist at the University of California, San Francisco, agreed. He added that people shouldn't be wary of drinking milk.


Read the full Reuters Health report here:

Milk intake in teens tied to later prostate cancer